Comparative Cardiovascular and Renal Effectiveness and Safety of Empagliflozin and Other SGLT2i in Patients With Type 2 Diabetes (T2D) With and Without Baseline Kidney Disease in the United States

Registration

Registration

NCT05465317

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

62197

Start

2022-08-08

Primary completion

2023-05-02

Lead sponsor

Boehringer Ingelheim

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG:Empagliflozin; DRUG:Dipeptidyl Peptidate-4 inhibitors

Results posted

TRUE

Individual participant data sharing

NO

Registered primary outcomes

• Incidence Rate of the Composite Outcome Including 40% Decline in Estimated Glomerular Filtration Rate (eGFR), Incident End-stage Renal Disease (ESRD) and All-cause Death [Starting the day after the index date (date of initiation of empagliflozin or DPP4i) and continuing until the first occurrence of the outcome of interest, or end of study date (date of death, date of study end, 2 years after index date). Up to 2 years.]